Introduction

Functional dyspepsia (FD) is a common functional gastrointestinal disorder of childhood defined by bothersome symptoms arising from the gastroduodenal region in the absence of an identifiable structural or biochemical explanation. Classified as category H2a under the Rome IV system, it belongs to the broader group of functional abdominal pain disorders (FAPDs) in children and adolescents. FD is notable for its clinical heterogeneity: the same diagnostic label encompasses patients with predominantly meal-related symptoms (fullness, early satiation) and those with primarily pain-driven presentations (epigastric pain or burning), which led Rome IV to formally adopt subtype classification for the pediatric population.

The Rome IV criteria for child functional dyspepsia represent an important evolution from earlier iterations. They shift away from requiring pain as a mandatory feature, introduce the Postprandial Distress Syndrome (PDS) and Epigastric Pain Syndrome (EPS) subtypes previously used only in adults, and endorse a positive diagnostic approach that does not depend on exhaustive testing. These changes reflect growing recognition that FD in children is a disorder of gut-brain interaction, driven by multiple overlapping pathophysiologic mechanisms rather than a single structural abnormality.

Historical Background: Evolution of the Pediatric Dyspepsia Criteria

The conceptual framework for functional dyspepsia in children has undergone substantial revision across successive Rome iterations. Each version has refined the diagnostic threshold, symptom definitions, and classification approach.

Rome II (1999) first addressed pediatric dyspepsia as a distinct entity, but the criteria were relatively broad and did not sharply distinguish dyspepsia from other forms of recurrent abdominal pain in children. The emphasis was on persistent or recurrent upper abdominal pain or discomfort, with the requirement that organic disease be excluded.

Rome III (2006) formalized the separation of functional abdominal pain disorders into distinct categories, including functional dyspepsia as a named entity. Rome III required upper abdominal pain or discomfort, meaning that pain was an obligatory component. Symptoms needed to occur at least once per week for at least two months. Subtype classification (PDS and EPS) was available for adults but was not formally adopted for children, in part because of limited pediatric validation data.

Rome IV (2016) introduced several pivotal changes. Pain is no longer mandatory; postprandial fullness or early satiation alone can now satisfy the core symptom requirement, capturing an important subset of children whose FD manifests primarily as meal-related discomfort rather than pain. The PDS and EPS subtypes were formally extended to the pediatric population. The frequency requirement was changed from "at least once per week" to "at least 4 days per month," which is functionally similar but provides greater precision. The exclusion criterion was reworded to reflect a positive diagnostic approach: "after appropriate evaluation, symptoms cannot be fully explained by another medical condition." This language explicitly supports making a confident diagnosis without exhaustive testing in the right clinical context.

Diagnostic Criteria

The Rome IV diagnostic criteria for child functional dyspepsia (H2a) require the following:

Must include one or more of the following bothersome symptoms at least 4 days per month:

#	Core Symptom	Description
1	Postprandial fullness	Bothersome fullness occurring after eating a regular-sized meal. The child reports an uncomfortable sensation of food remaining in the stomach longer than expected.
2	Early satiation	Feeling full sooner than expected after starting a meal, preventing the child from finishing a normal amount of food.
3	Epigastric pain or burning	Bothersome pain or a burning sensation localized to the upper abdomen (epigastrium). The pain is not associated with defecation, not relieved by passage of flatus, and not generalized to other abdominal regions.

Additionally:

• After appropriate evaluation, the symptoms cannot be fully explained by another medical condition.
• Criteria must be fulfilled for at least 2 months before diagnosis.

If at least one core symptom is present on at least 4 days per month for at least 2 months, and symptoms are not attributable to another medical condition, the patient fulfills the Rome IV criteria for child functional dyspepsia.

Symptom Definitions in Detail

Postprandial fullness is defined as an unpleasant sensation of prolonged food retention in the stomach after a regular-sized meal. The key distinction is that the sensation is disproportionate to the quantity of food consumed: the child feels uncomfortably full after eating an amount that would normally be well tolerated. This symptom is the hallmark of the Postprandial Distress Syndrome subtype.

Early satiation refers to the feeling of being full soon after starting to eat, to the point that the child cannot finish a normal meal. This should be distinguished from loss of appetite (anorexia), in which the child does not feel hungry and has little desire to eat. In early satiation, the child may begin the meal with a normal appetite but quickly feels that the stomach is "already full." Like postprandial fullness, this symptom maps to the PDS subtype.

Epigastric pain or burning is localized to the upper midline abdomen, between the xiphoid process and the umbilicus. The Rome IV criteria specifically require that this pain not be associated with defecation (to distinguish it from irritable bowel syndrome) and that it not be generalized to other abdominal quadrants. A burning quality (without a retrosternal component) is characteristic but not required. This symptom defines the Epigastric Pain Syndrome subtype.

Functional Dyspepsia Subtypes

Rome IV recognizes two subtypes of functional dyspepsia in children, adopted from the adult criteria. These subtypes have distinct symptom profiles and may reflect different underlying pathophysiologic mechanisms, which has implications for targeted management.

Subtype	Core Features	Supportive Features	Proposed Dominant Mechanism
Postprandial Distress Syndrome (PDS)	Bothersome postprandial fullness or early satiation that prevents finishing a regular meal	Upper abdominal bloating, postprandial nausea, excessive belching	Impaired gastric accommodation, delayed gastric emptying
Epigastric Pain Syndrome (EPS)	Bothersome epigastric pain or burning severe enough to interfere with normal activities. Not generalized; not relieved by defecation or flatus.	Burning quality without retrosternal component; pain commonly induced or relieved by ingestion of a meal but may occur while fasting	Visceral hypersensitivity, duodenal mucosal inflammation

Subtype Distribution in Children

In a pediatric study examining subtype distribution, approximately 29% of children with FD met criteria for PDS alone, 24% for EPS alone, 26% for both (overlap), and 21% did not fit neatly into either subtype. The substantial overlap group highlights that the two subtypes are not mutually exclusive and that mixed presentations are common in clinical practice. Rome IV explicitly permits simultaneous classification as both PDS and EPS when both symptom patterns are present.

The clinical utility of subtype classification lies primarily in guiding initial management: patients with PDS features may benefit more from prokinetic agents and dietary modification, while those with EPS features may respond preferentially to acid suppression. However, the evidence base for subtype-directed therapy in children remains limited.

Rome IV Functional Abdominal Pain Disorders in Children

Functional dyspepsia is one of four functional abdominal pain disorders (FAPDs) defined by Rome IV for children and adolescents. Understanding the broader FAPD classification is essential for accurate differential diagnosis, as the presenting symptoms often overlap.

Category	Disorder	Key Distinguishing Features
H2a	Functional dyspepsia	Postprandial fullness, early satiation, or epigastric pain/burning localized to the upper abdomen, not associated with defecation
H2b	Irritable bowel syndrome (IBS)	Abdominal pain associated with defecation or a change in bowel habit (frequency or form)
H2c	Abdominal migraine	Paroxysmal episodes of intense periumbilical or diffuse abdominal pain lasting at least 1 hour, with intervening periods of usual health. Often accompanied by anorexia, nausea, vomiting, headache, photophobia, or pallor.
H2d	Functional abdominal pain, not otherwise specified (FAP-NOS)	Episodic or continuous abdominal pain that does not meet criteria for FD, IBS, or abdominal migraine

Rome IV recognizes that more than one FAPD can coexist in the same patient. A child who has both meal-related upper abdominal symptoms (meeting FD criteria) and defecation-associated lower abdominal pain with altered stool pattern (meeting IBS criteria) may carry both diagnoses simultaneously. This represents a meaningful departure from earlier Rome versions, which tended to favor a single diagnosis.

Changes from Rome III to Rome IV

Several changes between Rome III and Rome IV have direct clinical implications for how functional dyspepsia is diagnosed and conceptualized in children.

Feature	Rome III (2006)	Rome IV (2016)
Core symptom requirement	Upper abdominal pain or discomfort required	Pain is no longer required; postprandial fullness or early satiation alone can fulfill criteria
Subtype classification	PDS and EPS not formally adopted for children	PDS and EPS subtypes adopted for children, mirroring adult criteria
Frequency requirement	At least once per week	At least 4 days per month
Duration requirement	At least 2 months	At least 2 months (unchanged)
Organic disease exclusion	"No evidence of organic disease"	"After appropriate evaluation, symptoms cannot be fully explained by another medical condition" (allows selective or no testing)
Coexistence with other FAPDs	Not explicitly addressed	Acknowledged; FD can coexist with IBS, abdominal migraine, or FAP-NOS in the same patient
Diagnostic philosophy	Primarily exclusionary	Positive, criteria-based diagnosis with selective testing based on clinical judgment

The removal of pain as a mandatory criterion is perhaps the most consequential change. Under Rome III, a child with bothersome postprandial fullness and early satiation who did not report pain could not be classified as having FD. Rome IV corrects this by recognizing that meal-related discomfort without frank pain is a legitimate and common presentation of gastroduodenal dysfunction. This broadens the diagnostic net while maintaining specificity through the requirement for symptom localization (upper abdomen/epigastrium), temporal association (at least 4 days per month for at least 2 months), and exclusion of alternative explanations.

Epidemiology

Functional dyspepsia in children is more common than often recognized, though prevalence estimates vary substantially depending on the criteria and methodology used.

• Community prevalence: Community-based studies estimate that 5% to 10% of otherwise healthy school-age children and adolescents report dyspeptic symptoms. When formal Rome criteria are applied, the prevalence is lower, reflecting the stringency of duration and frequency requirements.
• Rome III estimates: A US nationwide survey found that 1.4% of children had upper abdominal pain or discomfort at least once weekly, though only 0.2% met the full Rome III criteria for pediatric FD. The discrepancy highlights how many symptomatic children fall below the diagnostic threshold.
• Rome IV estimates: Rome IV criteria capture a slightly different population than Rome III due to the removal of mandatory pain and the change in frequency wording. Direct comparative prevalence data using Rome IV criteria are still emerging, but early studies suggest that the Rome IV criteria identify a moderately larger cohort of children with FD compared to Rome III, primarily by including patients whose presentation is dominated by postprandial fullness or early satiation without frank pain.
• Post-infectious FD: Approximately 24% of children developed FD following acute bacterial gastroenteritis in longitudinal studies. Viral gastroenteritis has not been as strongly associated, though rotavirus infection has been implicated as a potential trigger in some populations. Post-infectious FD may have a different natural history and prognosis compared to non-post-infectious forms.
• Overlap with other FAPDs: FD frequently coexists with other functional abdominal pain disorders. Studies suggest that 30% to 50% of children meeting criteria for one FAPD also meet criteria for at least one additional FAPD, reflecting shared pathophysiologic mechanisms.
• Healthcare utilization: Children with FD use significantly more healthcare resources than matched controls, including more outpatient visits, emergency department visits, and diagnostic procedures. The economic burden of pediatric FD is substantial, both in direct medical costs and in indirect costs related to school absenteeism and parental work disruption.

Pathophysiology

Functional dyspepsia in children is a disorder of gut-brain interaction with multiple, often overlapping pathophysiologic mechanisms. No single mechanism accounts for all presentations, which contributes to the clinical heterogeneity of the disorder and the variable response to different treatments.

Impaired Gastric Accommodation

Gastric accommodation is the reflex relaxation of the proximal stomach in response to food ingestion, mediated primarily by vagal pathways and nitric oxide-dependent mechanisms. In healthy individuals, accommodation allows the stomach to expand to receive a meal without a significant rise in intragastric pressure. Children with FD, particularly those with postprandial fullness and early satiation (PDS features), may have impaired gastric accommodation, demonstrated in pediatric barostat studies. The failure of the proximal stomach to relax appropriately leads to increased intragastric pressure during meals, triggering symptoms of fullness and inability to complete a normal-sized meal.

Gastric Dysmotility and Delayed Emptying

Abnormal gastric motility is demonstrable in a substantial proportion of children with FD. Approximately 50% of pediatric FD patients have abnormal electrogastrograms (EGGs), including both tachygastria and bradygastria. Delayed gastric emptying, documented by scintigraphy or breath testing, has been reported in roughly 47% of affected children. Delayed emptying is most strongly associated with PDS symptoms (postprandial fullness, nausea, bloating) rather than with epigastric pain.

However, the correlation between the degree of gastric emptying delay and symptom severity is imperfect. Some children with markedly delayed emptying have mild symptoms, while others with normal emptying studies have severe dyspepsia. This dissociation suggests that gastric emptying rate is one contributor among many, rather than the sole determinant of symptoms.

Visceral Hypersensitivity

Visceral hypersensitivity refers to an exaggerated perception of stimuli arising from the gastrointestinal tract. Barostat studies in adolescents with FD have demonstrated significantly lower sensory thresholds to balloon distention of the proximal stomach compared to healthy controls. The children perceive discomfort or pain at lower distention volumes, indicating that peripheral or central sensitization of visceral afferent pathways contributes to symptom generation.

Visceral hypersensitivity may be particularly relevant to the EPS subtype, in which epigastric pain occurs even in the absence of a clear provocative stimulus (such as a meal). Central processing of visceral signals may also be altered, with amplified cortical and limbic responses to gastric stimuli demonstrated in functional neuroimaging studies in adults.

Low-Grade Mucosal Inflammation

An important development in the understanding of pediatric FD has been the recognition that low-grade mucosal inflammation, particularly in the duodenum and gastric antrum, may play a pathophysiologic role. Studies have documented increased eosinophil and mast cell density in the gastric and duodenal mucosa of children with FD compared to healthy controls, even in the absence of gross endoscopic abnormalities.

• Duodenal eosinophilia: Elevated duodenal eosinophil counts have been reported in children with FD, with some studies demonstrating a correlation between eosinophil density and symptom severity. The clinical significance of duodenal eosinophilia in FD remains an area of active investigation.
• Mast cell infiltration: Increased mast cell numbers in the gastric antral mucosa and duodenum have been associated with specific FD symptoms. Nocturnal epigastric pain has been correlated with higher duodenal mast cell density. Mast cell mediators (histamine, proteases, cytokines) can sensitize visceral afferent nerve endings, providing a mechanistic link between low-grade inflammation and visceral hypersensitivity.
• Atopic association: Children with atopic conditions (allergic rhinitis, asthma, eczema) appear to have a higher prevalence of FD symptoms, possibly mediated through eosinophilic infiltration of the gastroduodenal mucosa.

Post-Infectious Sensitization

A significant subset of pediatric FD develops after an episode of acute infectious gastroenteritis. Longitudinal studies have shown that approximately 24% of children developed FD following bacterial gastroenteritis. The proposed mechanism involves persistent low-grade mucosal inflammation, altered mucosal permeability, and sensitization of enteric and visceral afferent neural pathways following the initial infection. Post-infectious FD may represent a distinct pathophysiologic subgroup with potentially different treatment responsiveness and prognosis compared to non-post-infectious FD.

Gut Microbiome Alterations

Emerging research suggests that the composition of the gastroduodenal and intestinal microbiome may differ in children with FD compared to healthy controls. Changes in microbial diversity, shifts in specific bacterial taxa, and alterations in microbial metabolite profiles have been reported. The microbiome may influence FD pathophysiology through effects on mucosal immune function, mucosal barrier integrity, enteric nervous system signaling, and production of neuroactive metabolites. However, the evidence base remains preliminary, and it is not yet clear whether microbiome alterations are causative, consequential, or coincidental.

Duodenal Factors

The duodenum has emerged as a site of particular pathophysiologic interest in FD. Beyond eosinophilic and mast cell infiltration, duodenal factors implicated in FD include increased mucosal permeability, altered expression of tight junction proteins, and abnormal duodenal acid exposure. These changes may contribute to activation of submucosal sensory nerves and generation of dyspeptic symptoms. Some investigators have proposed that the duodenum serves as a "gatekeeper" in FD pathophysiology, integrating signals from luminal contents, the mucosal immune system, and the enteric nervous system.

Psychological and Psychosocial Factors

Anxiety, depression, and somatization are commonly associated with FD in children and adolescents. The relationship is bidirectional: psychological distress can amplify visceral perception and modify central processing of gut signals (top-down pathway), while chronic gastrointestinal symptoms can generate or exacerbate psychological distress (bottom-up pathway). Specific associations have been noted:

• Early satiation and postprandial fullness correlate with higher depression and anxiety scores.
• Nocturnal epigastric pain correlates with higher duodenal mast cell density but also with greater anxiety levels, suggesting interaction between mucosal and psychological factors.
• Stressful life events, adverse childhood experiences, and maladaptive coping styles are reported more frequently in children with FAPDs, including FD.

These associations underscore the importance of screening for psychological comorbidities as part of a comprehensive evaluation and of integrating psychological interventions into the management plan when appropriate.

Clinical Evaluation

The Rome IV framework supports a positive diagnostic approach to functional dyspepsia. In most cases, a thorough history and focused physical examination, combined with the absence of alarm features, are sufficient to make a confident diagnosis without extensive testing.

History

The clinical history should systematically address each of the three core symptoms (postprandial fullness, early satiation, epigastric pain or burning), their frequency, duration, and relationship to meals. Key historical elements include:

• Character, location, and radiation of any pain (epigastric vs. periumbilical vs. diffuse; relationship to meals and defecation)
• Meal-related symptoms: timing of fullness relative to meal completion, portion sizes the child can tolerate, and any specific food triggers
• Associated symptoms: nausea, vomiting, bloating, belching, heartburn, regurgitation
• Bowel habit: frequency, consistency (Bristol Stool Form Scale), and any association between abdominal symptoms and defecation (to differentiate from IBS)
• Impact on daily function: school attendance, participation in activities, sleep disruption
• Medication history: NSAIDs, antibiotics, acid suppressants, and response to prior treatments
• Dietary history: fiber, fluid, caffeine, spicy foods, dietary restrictions
• Psychosocial history: anxiety, depression, school stressors, family dynamics, adverse childhood experiences
• Family history: peptic ulcer disease, Helicobacter pylori infection, inflammatory bowel disease, celiac disease, functional GI disorders

Physical Examination

The physical examination is typically normal in children with FD. A focused examination should include assessment of growth parameters (weight, height, BMI plotted on growth curves), abdominal examination for tenderness (especially epigastric), organomegaly, and masses. A general examination should assess for signs of systemic disease (pallor, jaundice, rash, joint abnormalities, perianal disease) that might suggest an organic etiology.

Role of Esophagogastroduodenoscopy (EGD)

The role of EGD in the diagnostic evaluation of pediatric FD remains an area of active debate. The Rome IV pediatric committee does not require EGD to make a diagnosis of FD but acknowledges that local practice patterns and clinical judgment influence the decision. EGD may be considered in the following situations:

• Children with a family history of peptic ulcer disease or H. pylori infection
• Children older than 10 years of age
• Symptoms persisting for more than 6 months despite appropriate empiric treatment
• Symptoms severe enough to affect activities of daily living, including sleep
• Presence of alarm features

When EGD is performed, biopsies should be obtained from the esophagus, gastric antrum, gastric body, and duodenum (including the duodenal bulb) to evaluate for H. pylori gastritis, eosinophilic esophagitis, eosinophilic gastritis or duodenitis, celiac disease, and other mucosal pathology. It is important to note that there is no evidence that H. pylori gastritis causes dyspeptic symptoms in children in the absence of peptic ulcer disease (gastric or duodenal ulcer). Eradication of H. pylori in a child with FD-like symptoms and nodular gastritis but without ulceration does not reliably resolve symptoms.

Other Investigations

Routine laboratory testing is generally not indicated when the clinical presentation is characteristic and alarm features are absent. When testing is pursued based on clinical judgment, commonly considered investigations include:

• Complete blood count (to screen for anemia or leukocytosis)
• Erythrocyte sedimentation rate or C-reactive protein (to screen for inflammation)
• Celiac serologies (tissue transglutaminase IgA with total IgA)
• Liver function tests and lipase (if biliary or pancreatic pathology is considered)
• Stool studies (H. pylori stool antigen, calprotectin, ova and parasites) as clinically indicated

Abdominal ultrasound may be considered if biliary or pancreatic pathology is suspected based on symptom pattern or laboratory findings. Gastric emptying studies (scintigraphy or breath test) are typically reserved for refractory cases or when gastroparesis is specifically suspected.

Alarm Features Warranting Further Investigation

The following alarm features should prompt additional evaluation to exclude organic disease before applying a functional dyspepsia diagnosis:

• Family history of inflammatory bowel disease, celiac disease, or peptic ulcer disease
• Persistent right upper or right lower quadrant pain
• Dysphagia or odynophagia
• Persistent vomiting
• Gastrointestinal blood loss (hematemesis, melena, hematochezia)
• Nocturnal diarrhea
• Arthritis
• Perirectal disease (fissures, fistulae, skin tags)
• Involuntary weight loss
• Deceleration of linear growth
• Delayed puberty
• Unexplained fever

The presence of alarm features does not automatically establish an organic diagnosis, but it shifts the pretest probability sufficiently to warrant targeted investigation before the diagnosis of FD is finalized.

Differential Diagnosis

The differential diagnosis of upper abdominal symptoms in children encompasses both organic and functional conditions. A systematic approach helps ensure that treatable organic conditions are not overlooked while avoiding unnecessary testing in children with characteristic functional presentations.

Category	Conditions
Acid-related	Gastroesophageal reflux disease (GERD), peptic ulcer disease (gastric or duodenal), H. pylori-associated ulceration, erosive esophagitis
Eosinophilic	Eosinophilic esophagitis, eosinophilic gastritis, eosinophilic duodenitis
Inflammatory	Crohn disease (upper GI involvement), celiac disease
Hepatobiliary/Pancreatic	Cholelithiasis, biliary dyskinesia, pancreatitis (acute or chronic)
Motility disorders	Gastroparesis, superior mesenteric artery syndrome, chronic intestinal pseudo-obstruction
Medication-related	NSAID gastropathy, iron supplement intolerance, antibiotic-associated dyspepsia
Other functional GI disorders	IBS (if pain is associated with defecation), abdominal migraine (if episodic with intervening wellness), FAP-NOS
Systemic	Diabetes mellitus (gastroparesis), connective tissue disorders, eating disorders (anorexia nervosa, avoidant/restrictive food intake disorder)

The distinction between FD and gastroparesis deserves particular mention. Both conditions share symptoms (postprandial fullness, nausea, early satiation), and delayed gastric emptying is present in a subset of FD patients. Rome IV classifies gastroparesis and FD as overlapping conditions on a spectrum of gastric neuromuscular dysfunction, differing primarily in the degree of emptying delay. A child with characteristic FD symptoms and documented severely delayed gastric emptying may be more appropriately labeled as having gastroparesis, which may influence management decisions.

Management Considerations

Management of functional dyspepsia in children is multimodal, combining education, dietary modifications, pharmacological therapy tailored to the predominant symptom pattern, and attention to psychological comorbidities. It is important to acknowledge that no adequately powered, double-blind, placebo-controlled trials specifically in pediatric FD exist. Most management recommendations are extrapolated from adult data or derived from small pediatric studies and expert consensus.

Education and Reassurance

As with all functional gastrointestinal disorders, the cornerstone of management is clear, empathetic education. Families should understand that FD is a real, recognized medical condition, not "all in the child's head." The concept of gut-brain interaction should be explained in age-appropriate terms: the stomach and the brain communicate constantly, and in FD, this communication is amplified or disordered, leading to symptoms that are genuine even though no structural abnormality is found. Setting realistic expectations is important: treatment aims to reduce symptom severity and improve function, and complete symptom elimination may not be achievable in all cases.

Dietary Modifications

Dietary interventions are first-line and include:

• Avoiding foods and beverages that aggravate symptoms: caffeine-containing drinks, spicy foods, fatty or greasy foods, and carbonated beverages are commonly implicated triggers.
• Smaller, more frequent meals rather than large meals, particularly for children with PDS features.
• Avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs), which can exacerbate gastric mucosal irritation.
• Adequate hydration and a balanced diet to maintain overall nutritional status.

Pharmacological Therapy

Approach	Target Subtype	Details
Acid suppression (PPIs)	EPS (pain/burning predominant)	Proton pump inhibitors (e.g., omeprazole, lansoprazole) are first-line pharmacotherapy for epigastric pain or burning. Omeprazole has been shown to be superior to H2 receptor antagonists (ranitidine, famotidine, cimetidine) for complete relief after 4 weeks in pediatric studies. Treatment is typically for 4 to 8 weeks with reassessment.
H2 receptor antagonists	EPS (milder symptoms)	May be considered for milder EPS symptoms or as a step-down from PPI therapy. Less effective than PPIs for complete symptom relief.
Prokinetics	PDS (fullness, nausea, early satiation)	Nausea, bloating, and early satiety are more difficult to treat than pain. Domperidone (a peripheral dopamine D2 receptor antagonist) can be offered where available. Erythromycin (a motilin receptor agonist) at sub-antimicrobial doses has been used in selected refractory cases. The evidence for prokinetics in pediatric FD is limited.
Cyproheptadine	PDS, mixed	Cyproheptadine is an antihistamine with antiserotonergic and calcium channel blocking properties that may improve gastric accommodation. Retrospective pediatric data suggest safety and efficacy for dyspeptic symptoms, particularly nausea and early satiation. It also has appetite-stimulating properties, which may be beneficial in children with weight loss or poor intake.
Neuromodulators (low-dose TCAs)	Refractory FD	Low-dose tricyclic antidepressants (amitriptyline, imipramine) may be considered in refractory cases, particularly when pain is the dominant symptom. Their mechanism in FD is likely through modulation of visceral afferent signaling and central pain processing rather than antidepressant effects. Evidence in pediatric FD is limited but extrapolated from adult trials where TCAs demonstrated benefit over placebo.

Psychological Interventions

Given the strong association between FD and psychological comorbidities, psychological interventions should be integrated into management when appropriate:

• Cognitive behavioral therapy (CBT): Structured CBT programs targeting pain-related cognitions, maladaptive coping strategies, and behavioral avoidance have demonstrated efficacy in pediatric FAPDs. Evidence specific to the FD subtype is limited but extrapolated from broader FAPD trials.
• Gut-directed hypnotherapy: Hypnotherapy targeting visceral sensations and gut-brain communication has shown promise in pediatric FAPD studies, with some evidence of sustained benefit at follow-up.
• Mindfulness and relaxation techniques: These may be helpful as adjunctive strategies, particularly for children with significant anxiety.

Referral for psychological evaluation and therapy should be framed positively, as an integral part of comprehensive management rather than an implication that symptoms are "psychological" or not real.

Interpreting Criteria Results

When applying the Rome IV criteria for child functional dyspepsia, three elements must all be satisfied for a positive diagnosis:

1. Core symptom requirement: At least 1 of the 3 core symptoms (postprandial fullness, early satiation, epigastric pain or burning) is present and bothersome.
2. Duration and frequency: Symptoms occur at least 4 days per month for at least 2 months.
3. Exclusion: After appropriate evaluation, symptoms cannot be fully explained by another medical condition.

When all three elements are met, the patient fulfills the Rome IV criteria for child functional dyspepsia. Subtype classification should then be applied:

• PDS if postprandial fullness or early satiation is present.
• EPS if epigastric pain or burning is present.
• Overlap (PDS + EPS) if features of both subtypes are present.
• Unspecified if the presentation does not clearly map to either subtype (uncommon when using the standard three-symptom checklist).

If criteria are not met, clinicians should consider whether the duration or frequency threshold has not yet been reached (and the patient may qualify on reassessment), whether symptoms are better explained by another FAPD (IBS if associated with defecation, abdominal migraine if episodic with intervening wellness), or whether an organic cause should be investigated.

Limitations of the Rome IV Criteria for Child Functional Dyspepsia

• Symptom overlap: FD symptoms overlap significantly with IBS, abdominal migraine, and other functional abdominal pain disorders. The distinguishing feature (association with defecation for IBS, epigastric localization not associated with defecation for FD) may be difficult to elicit reliably in younger children. Rome IV acknowledges this by permitting concurrent FAPD diagnoses.
• Subjective symptom reporting: The criteria depend on patient- or parent-reported symptoms, which are influenced by recall bias, symptom perception, and developmental stage. Younger children (under 8 to 10 years) may have difficulty articulating concepts such as "early satiation" or "postprandial fullness," potentially leading to underdiagnosis in this age group.
• Limited pediatric treatment evidence: No adequately sized, double-blind, placebo-controlled trials of FD-specific treatment exist in children. Management recommendations are largely extrapolated from adult studies or based on small, often retrospective, pediatric series. The subtype-directed treatment paradigm (acid suppression for EPS, prokinetics for PDS) has not been validated in children through prospective trials.
• Subtype classification not fully validated: While the PDS and EPS subtypes have been formally adopted for the pediatric population, prospective validation studies confirming their clinical utility, stability over time, and treatment-response prediction in children are still needed.
• EGD role undefined: There is no consensus on when endoscopy is required versus when a clinical diagnosis alone is sufficient. Practice varies by institution, region, and individual clinician judgment. This variability means that the Rome IV criteria may be applied at different levels of diagnostic certainty in different settings.
• Frequency threshold: The "at least 4 days per month" requirement, while more precise than Rome III's "at least once per week," may still exclude children with infrequent but severe symptoms that significantly impair quality of life. Clinical judgment should complement criteria-based diagnosis.
• Cultural and dietary variation: Normal eating patterns, portion sizes, and perceptions of "fullness" vary across cultures. The criteria were developed primarily from data in Western populations and may not equally capture dyspeptic presentations in all cultural and dietary contexts.

Practice Caveats

• A positive diagnosis of functional dyspepsia should be made confidently based on the characteristic symptom pattern and the absence of alarm features, rather than through exhaustive exclusionary testing. Rome IV explicitly encourages this approach. Communicating the diagnosis with confidence helps reduce family anxiety and avoids the cycle of unnecessary investigations.
• Younger children (under 8 to 10 years) may not reliably describe "fullness," "satiation," or "epigastric burning." In these patients, clinician interpretation of the child's behavior (e.g., stopping eating early, refusing meals, clutching the upper abdomen) and parental input are essential for symptom characterization.
• Screen for anxiety and depression in all children evaluated for FD. Psychological comorbidities are common, influence symptom severity, and should inform the treatment plan. Validated screening tools (e.g., GAD-7, PHQ-A, SCARED) can be integrated into the clinical workflow.
• There is no evidence that H. pylori gastritis (in the absence of peptic ulceration) causes dyspeptic symptoms in children. The decision to test for and treat H. pylori should be based on the presence of mucosal ulceration or other established indications, not solely on a FD diagnosis.
• Reassess the diagnosis if new symptoms develop, alarm features emerge, the child fails to respond to appropriate management within 2 to 3 months, or the clinical course changes in an unexpected way. Functional diagnoses are not permanent labels; they require ongoing clinical reassessment.
• When prescribing proton pump inhibitors, use the lowest effective dose for the shortest appropriate duration. Long-term PPI use in children carries potential risks (vitamin and mineral malabsorption, increased infection risk) that should be weighed against symptom benefit.